TY - JOUR AU - Tu, Hai-Yan AU - Zhang, Qi AU - Wu, Yi-Long PY - 2017 TI - Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed JF - Journal of Thoracic Disease; Vol 9, No 12 (December 29, 2017): Journal of Thoracic Disease Y2 - 2017 KW - N2 - The advent of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) checkpoint inhibitors has made dramatic progress for the treatment of non-small cell lung cancer (NSCLC). In several series of clinical studies, anti-PD-1/PD-L1 antibodies have generated durable effects, leading to long-term survival with manageable toxicity for patients with advanced NSCLC (1-6). The potential of these agents to generate durable clinical responses has led to their rapid uptake as standard therapy. UR - https://jtd.amegroups.org/article/view/17115